Researchers at the UCLA (University of California, Los Angeles) have developed a new methodology to predict the reason behind the varied response of some patients battling advanced melanoma to the new breakthrough drug pembrolizumab (Keytruda). The study, led by UCLA Jonsson Comprehensive Cancer Center members Drs. Paul Tumeh and Antoni Ribas, primary investigator of pembrolizumab, is the first of its kind since the FDA approved the use of Keytruda in September ...
Read MoreYou have just read an article categorized health
titled Researchers Discover Reason Behind Patient's Mixed Response to a Melanoma Breakthrough Drug.
Written by:
editor - Thursday, November 27, 2014
There are currently no comments for "Researchers Discover Reason Behind Patient's Mixed Response to a Melanoma Breakthrough Drug"
Post a Comment